Market Cap 5.70B
Revenue (ttm) 482.38M
Net Income (ttm) 106.14M
EPS (ttm) N/A
PE Ratio 42.68
Forward PE 29.20
Profit Margin 22.00%
Debt to Equity Ratio 0.00
Volume 742,400
Avg Vol 851,262
Day's Range N/A - N/A
Shares Out 104.78M
Stochastic %K 99%
Beta 0.56
Analysts Strong Sell
Price Target $74.90

Latest News on CORT

Corcept Therapeutics' ALS drug fails in mid-stage trial

Dec 11, 2024, 5:27 PM EST - 5 weeks ago

Corcept Therapeutics' ALS drug fails in mid-stage trial


Corcept Therapeutics: A Most Promising And Compelling Biotech

Nov 27, 2024, 8:00 AM EST - 7 weeks ago

Corcept Therapeutics: A Most Promising And Compelling Biotech


Corcept: Key Announcements Coming Soon

Oct 15, 2024, 9:43 AM EDT - 3 months ago

Corcept: Key Announcements Coming Soon


3 Small Biotech Stocks With The 'Big Mo' Right Now

Sep 19, 2024, 12:54 PM EDT - 4 months ago

3 Small Biotech Stocks With The 'Big Mo' Right Now

AUPH VRDN


Corcept Therapeutics Announces Final Results of Tender Offer

Apr 5, 2023, 4:05 PM EDT - 1 year ago

Corcept Therapeutics Announces Final Results of Tender Offer


Corcept Therapeutics Initiates CATALYST Clinical Trial

Mar 28, 2023, 4:05 PM EDT - 1 year ago

Corcept Therapeutics Initiates CATALYST Clinical Trial


Corcept Investor Alert

Sep 14, 2022, 5:44 PM EDT - 2 years ago

Corcept Investor Alert